← Leaderboards
Derek Leroith
Diabetes, Digestive, Kidney Diseases
$7,337,784
Attributed
$8,896,260
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.3M · FY2008–22$2M$1.5M$1M$500K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$8,896,260 · 4
By mechanism
R01$8,727,260 · 3
R56$169,000 · 1
Top collaborators
- Nina A Bickell7 shared
Most similar at Diabetes, Digestive, Kidney Diseases
Same institution · by research overlap
Others in their field
Top investigators on “Growth”
- Eric Jeffrey Topol · Cleveland Clinic Lerner Col/Med-Cwru$233,131,631
- Albert Lazzarini · California Institute Of Technology$170,110,000
- David H Reitze · University Of Florida$170,110,000
- Garret A Fitzgerald · University Of Pennsylvania$153,184,124
- David Heimbrook · Leidos Biomedical Research, Inc.$143,966,408
- Carol Nesel · Westat$116,355,411
Research focus
GrowthInsulin ReceptorObesityWomanAnimal ModelTumorMediatingReceptor ExpressionMalignant Breast NeoplasmNon-Insulin-Dependent Diabetes MellitusInsulinOutcome ForecastHyperinsulinismAffectPathway InteractionsMammary NeoplasmsAggressive BehaviorTumor GrowthMalignant NeoplasmsEpidemiologic StudiesNeoplasm MetastasisMouse ModelCellsReceptor
Grant awards (49)
Mechanisms for the pro-metastatic effects of hyperinsulinemia on breast cancer$169,000
R56 · FY2022 · CA · contact PI
Obesity and triple negative breast cancer; the role of hypercholesterolemia$387,731
R01 · FY2020 · CA · contact PI
Obesity and triple negative breast cancer; the role of hypercholesterolemia$376,098
R01 · FY2019 · CA · contact PI
Obesity and triple negative breast cancer; the role of hypercholesterolemia$387,731
R01 · FY2018 · CA · contact PI
Mechanisms for the pro-metastatic effects of hyperinsulinemia on breast cancer$380,225
R01 · FY2018 · CA · contact PI
Insulin Resistance and Breast Cancer Prognosis in Black & White Women$525,063
R01 · FY2017 · CA
Obesity and triple negative breast cancer; the role of hypercholesterolemia$387,731
R01 · FY2017 · CA · contact PI
Mechanisms for the pro-metastatic effects of hyperinsulinemia on breast cancer$380,225
R01 · FY2017 · CA · contact PI
Insulin Resistance and Breast Cancer Prognosis in Black & White Women$491,333
R01 · FY2016 · CA
Obesity and triple negative breast cancer; the role of hypercholesterolemia$387,731
R01 · FY2016 · CA · contact PI
Mechanisms for the pro-metastatic effects of hyperinsulinemia on breast cancer$380,225
R01 · FY2016 · CA · contact PI
Insulin Resistance and Breast Cancer Prognosis in Black & White Women$659,497
R01 · FY2015 · CA
Mechanisms for the pro-metastatic effects of hyperinsulinemia on breast cancer$380,225
R01 · FY2015 · CA · contact PI
Mechanisms for the pro-metastatic effects of hyperinsulinemia on breast cancer$380,225
R01 · FY2014 · CA · contact PI
Insulin Resistance and Breast Cancer Prognosis in Black & White Women$1
R01 · FY2014 · CA
Insulin Resistance and Breast Cancer Prognosis in Black & White Women$678,794
R01 · FY2013 · CA
Mechanisms for Increased Breast Cancer Risk in Type 2 Diabetes$42,375
R01 · FY2013 · CA · contact PI
Insulin Resistance and Breast Cancer Prognosis in Black & White Women$40,936
R01 · FY2013 · CA
Insulin Resistance and Breast Cancer Prognosis in Black & White Women$721,329
R01 · FY2012 · CA
Mechanisms for Increased Breast Cancer Risk in Type 2 Diabetes$338,206
R01 · FY2012 · CA · contact PI
Mechanisms for Increased Breast Cancer Risk in Type 2 Diabetes$338,206
R01 · FY2011 · CA · contact PI
Mechanisms for Increased Breast Cancer Risk in Type 2 Diabetes$348,666
R01 · FY2010 · CA · contact PI
Mechanisms for Increased Breast Cancer Risk in Type 2 Diabetes$348,666
R01 · FY2009 · CA · contact PI
Mechanisms for Increased Breast Cancer Risk in Type 2 Diabetes$366,041
R01 · FY2008 · CA · contact PI
A Model of Type 2 Diabetes in the Mouse$0
Z01 · FY2005 · DK
Insulin-like Growth Factor-1 Receptor$0
Z01 · FY2005 · DK
Insulin-like Growth Factors$0
Z01 · FY2005 · DK
Acromegaly Treatment And Natural History$0
Z01 · FY2005 · DK
Insulin-like Growth Factor-1 Receptor$0
Z01 · FY2004 · DK
A Model of Type 2 Diabetes in the Mouse$0
Z01 · FY2004 · DK
Acromegaly Treatment And Natural History$0
Z01 · FY2004 · DK
Insulin-like Growth Factors$0
Z01 · FY2004 · DK
Insulin-like Growth Factors$0
Z01 · FY2003 · DK
A Model of Type 2 Diabetes in the Mouse$0
Z01 · FY2003 · DK
Acromegaly Treatment And Natural History$0
Z01 · FY2003 · DK
Insulin-like Growth Factor-1 Receptor$0
Z01 · FY2003 · DK
Insulin-like Growth Factors$0
Z01 · FY2002 · DK
Acromegaly Treatment And Natural History$0
Z01 · FY2002 · DK
Insulin-like Growth Factor-1 Receptor$0
Z01 · FY2002 · DK
Sulfonylurea Receptor$0
Z01 · FY2001 · DK
Acromegaly Treatment And Natural History$0
Z01 · FY2001 · DK
Sandostatin Lar Vs. Surgery In Acromegalics With Macroad$0
Z01 · FY2001 · DK
Insulin-like Growth Factors$0
Z01 · FY2001 · DK
Insulin-like Growth Factor-1 Receptor$0
Z01 · FY2001 · DK
SULFONYLUREA RECEPTOR$0
Z01 · FY2000 · DK
ACROMEGALY TREATMENT AND NATURAL HISTORY$0
Z01 · FY2000 · DK
SANDOSTATIN LAR VS. SURGERY IN ACROMEGALICS WITH MACROADENOMA$0
Z01 · FY2000 · DK
INSULIN-LIKE GROWTH FACTORS$0
Z01 · FY2000 · DK
INSULIN-LIKE GROWTH FACTOR-1 RECEPTOR$0
Z01 · FY2000 · DK